Geovax presents corporate update at the h.c. wainwright 25th annual global investment conference

Updates presented for gedeptin® and geo-cm04s1 phase 2 clinical trials atlanta, ga, sept. 12, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing  immunotherapies and vaccines against cancers and infectious diseases, today announced that its chairman and ceo, david dodd, presented a company overview during the h.c.
GOVX Ratings Summary
GOVX Quant Ranking